The AI‑driven drug discovery firm, recently separated from Alphabet’s DeepMind, is in early discussions for a new financing round that may value the company at up to $50 billion.

Isomorphic Labs, the AI‑driven drug‑discovery spin‑out from Alphabet’s DeepMind, has entered early fundraising talks that could lift its valuation to as much as $50 billion.

Background on Isomorphic Labs

Founded in 2022, Isomorphic Labs leverages large‑language‑model techniques to predict protein structures and design novel therapeutics, aiming to accelerate the drug‑development pipeline and reduce costs.

The company emerged from DeepMind’s AlphaFold breakthroughs, inheriting a team of leading AI researchers and biologists who have already published several high‑impact papers on protein folding and small‑molecule design.

Fundraising Momentum

Sources indicate that Isomorphic Labs is in “early discussions” with a mix of venture capital firms, sovereign wealth funds, and strategic investors. While the exact amount sought has not been disclosed, the talks are framed around a potential $40‑$50 billion valuation range.

If the round closes at the upper end of that range, Isomorphic would join an elite group of AI‑powered biotech firms valued above $30 billion, underscoring the market’s appetite for deep‑tech approaches to drug discovery.

Strategic Implications

A valuation of this magnitude would provide Isomorphic Labs with the capital needed to expand its computational platform, increase its pipeline of candidate molecules, and deepen collaborations with pharmaceutical partners.

Analysts suggest that the infusion could also accelerate the company’s move from early‑stage research to clinical‑stage programs, potentially reshaping the competitive landscape for biotech innovators.

  • Scale up AI infrastructure and data resources
  • Broaden partnership network with major pharma companies
  • Advance multiple therapeutic candidates into pre‑clinical trials
  • Recruit additional AI and life‑science talent
“The scale of investment we’re discussing reflects confidence that AI can fundamentally transform how medicines are discovered,” a senior Isomorphic Labs executive said.

The fundraising effort follows a broader trend of large‑scale capital inflows into AI‑focused biotech, where investors are betting on the ability of machine learning to cut development timelines and improve success rates.

The Fund coverage of Isomorphic Labs’ valuation talks